Ethylflualprazolam
The following information was compiled in April 2026 and is subject to change as new research is conducted and as new information becomes available:
Description: Ethylflualprazolam is a novel benzodiazepine classified as a triazolobenzodiazepine and bears structural similarity to other traditional and novel benzodiazepines (e.g., flualprazolam, alprazolam). There is little data in the literature investigating the pharmacology and potency of ethylflualprazolam; however, it is hypothesized to have similar pharmacological activity to flualprazolam. Studies show flualprazolam has a greater binding affinity for GABAA receptors than other designer benzodiazepines including clobromazolam, desalkylgidazepam, and gidazepam.1,2 Ethylflualprazolam has been detected in one drug material to date at the CFSRE and was identified alongside 4’-Cl deschloroalprazolam. The sample was a rectangular blue tablet labeled “B707” and originated from Georgia. Ethylflualprazolam has not been detected in toxicology specimens to date at the CFSRE. Ethylflualprazolam is not currently scheduled in the United States.
- Class:
- Benzodiazepine
- Appearance:
- Drug Material
- Formula:
- C18H14ClFN4
- MW:
- 340.8
- [M+]:
- 340
- [M+H]+:
- 341.0964
- IUPAC:
- 8-chloro-1-ethyl-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
- Report Date:
- April 28, 2026
